Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Prometheus Biosciences $500 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Amgen $28.5 billion Horizon Therapeutics acquisition financing
We advised the lender parties on the financing
Lantheus Holdings $575 million convertible senior notes offering
The 2.625% convertible notes are due 2027
IVERIC bio $324.7 million stock offering
The shares are listed on the Nasdaq Global Select Market
Biodesix $40 million follow-on offering
The shares are listed on the Nasdaq Global Market
RAPT Therapeutics $75 million follow-on offering
The shares are listed on the Nasdaq Global Market
TMS ¥2.9 billion global IPO
The shares are listed on the Tokyo Stock Exchange
Brookdale Senior Living $125 million tangible equity units offering
The offering comprised 2.5 million units
Privia Health $135 million secondary offering
We advised Privia on its debut shelf takedown offering
Tenaya Therapeutics $75 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market